Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Botanical Review Team Develops “Post-CMC” Approach

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s Botanical Review Team has identified new ways to help assure the quality of complex natural mixtures. While not specified in the agency’s 2004 guidance on botanical drugs, the team is adding its “post-CMC” approach to conventional CMC analyses and “pre-CMC” agricultural oversight.

You may also be interested in...

Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design

Review documents show that Fulyzaq’s clear, if modest, treatment effect compared to placebo was buttressed by a series of exploratory subgroup analyses suggesting greater efficacy in sicker patients.

US FDA’s Median Review Time For Novel Drugs Held Steady In 2020

Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.

Breakthroughs, Orphans Hit High Notes As US FDA’s 2020 Novel Approvals Play A Familiar Tune

Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts